“Since the Company’s inception, it has been our commitment to serve the needs of the rare disease community in extraordinary ways,” stated
Amicus’ 2024 ESG initiatives are consistent with those identified by the
Highlights from the 2024 ESG Report:
Environment. Committed to practicing environmental responsibility and identifying and implementing sustainability objectives in our operations, and with our manufacturing and supply partners, to achieve a reduction in greenhouse gas (GHG) emissions.
- Joined the CDP Supply Chain Program to engage directly with our partners and consolidate environmental information across our entire supply chain.
- Continued to have excellent oversight of climate-related risks by identifying and implementing metrics to support oversight.
Patients. Continued to prioritize our patient-focused mission to support individuals and families affected by rare disease, meet the unmet needs of the rare disease community, and support full access to education, diagnosis, medication, and service provision for rare diseases.
- Delivered our innovative medicines to >2,600 individuals worldwide through commercial, clinical, and expanded access programs at the end of 2023.
- Collaborated with internal and external stakeholders on strengthening health equity in our clinical trials and the rare disease space.
Employees. Progressed and enhanced our transparent, inclusive, and collaborative culture to give employees the tools and resources to grow personally and professionally while ensuring we can meaningfully engage with the global rare disease community.
- Continued efforts to support employee development, advancement, and retention through our robust learning and leadership development programs.
- In
February 2024 , Amicus was certified as aGreat Place to Work inthe United States ,United Kingdom ,Italy ,Germany ,Spain ,France , andJapan .
Governance. Maintained a strong culture of business ethics and integrity to ensure that the Company is managed for the long-term benefit of all our stakeholders.
- Amicus Board of Directors recognized by
The Forum of Executive Women as a 2023 Champion of Board Diversity for having a Board of Directors where women account for more than 30% of the Board. - 100% of employees received annual training on the Global Code of Conduct, data protection cybersecurity, and social media.
- Robust Board oversight of risk and the Enterprise Risk Management Program.
To access the full 2024 ESG Report, please visit www.amicusrx.com/responsibility/environmental-social-governance/.
About Amicus Therapeutics
CONTACT:
Investors:
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Head of
dmoore@amicusrx.com
(609) 662-5079
FOLD-G
Source:
2024 GlobeNewswire, Inc., source